Why Is Mankind Pharma Share Price Falling? Key Reasons and Share Price Target
- April 14, 2026
- Posted by: Kashish Aggarwal
- Category: News
Mankind Pharma (NSE: MANKIND) share price has fallen -33% from its 52-week high of Rs 2,800 to Rs 1,850 — making it one of the most-searched stocks on investor platforms in April 2026. This analysis covers the key reasons for the fall, financial performance, technical levels, and the Mankind Pharma share price target for 2026.
Click Here — Get Free Investment Predictions on Univest.
About Mankind Pharma
Mankind Pharma is India’s fourth-largest pharma company by volume — and arguably the strongest brand-builder in Indian OTC health. Prega News, Gas-O-Fast, Unwanted-72, and AcneStar are market-leading consumer health brands.
Why Is Mankind Pharma Share Price Falling? Key Reasons
Tap to Access Best Research Pieces on Univest.
1. Market Valuation Reset
India pharma market growth decelerating to 7% — below the 10%+ that justifies 42x PE.
2. Sector Headwinds
Integration of BSV Group (Rs 13,600 crore acquisition) — complexity ahead of revenue synergies.
3. Company-Specific Pressure
Prescription market share below branded peers — Mankind’s strength is OTC and MR-visited trade generics.
4. Institutional Sentiment
Promoter sell-down — Ramesh Juneja family sold Rs 4,800 crore stake at IPO and subsequent blocks.
Financial Performance & Technical Signals
| Parameter | Value |
| CMP | Rs 1,850 |
| 52-Week High | Rs 2,800 |
| 52-Week Low | Rs 1,650 |
| Market Cap | Rs 74,000 Cr |
| Trailing P/E | 42x |
| Analyst Target (Base) | Rs 2,200 |
| Analyst Target (Bull) | Rs 2,500 |
| Upside to 12M Target | 19–35% |
Track Mankind Pharma live on the Univest Screener — real-time fundamentals and analyst ratings.
Download the Univest iOS App or Univest Android App for live Mankind Pharma price and SEBI-registered research.
Mankind Pharma Share Price Target
Subscribe to Univest Pro for Premium Stock Research on Mankind Pharma.
12-Month Analyst Consensus Target
The analyst consensus 12-month target for Mankind Pharma is Rs 2,200 to Rs 2,500 — implying 19–35% upside from the current price of Rs 1,850. These are analyst projections and not guaranteed returns.
Recovery Catalysts
Consumer health brands — Prega News 72% market share. BSV Women’s Health adding critical care.
Mankind Pharma Share Price Target Analysis
Short-term Rs 2,000–2,200; 12-month Rs 2,200–2,500; long-term Rs 3,000–3,500.
Conclusion
Mankind Pharma at Rs 1,850 has corrected -33% from its 52-week high of Rs 2,800. The reasons for the fall are specific and identifiable — india pharma market growth decelerating to 7% — below the 10%+ that justifies 42x pe. The 12-month analyst consensus target of Rs 2,200–Rs 2,500 implies 19–35% upside when the recovery catalysts materialise.
This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.
For more analysis, visit Univest Blogs.
Frequently Asked Questions
Q: Why is Mankind Pharma share price falling?
Mankind Pharma fell -33% from its 52-week high of Rs 2,800 to Rs 1,850. Key reasons: India pharma market growth decelerating to 7% — below the 10%+ that justifies 42x PE and Integration of BSV Group (Rs 13,600 crore acquisition) — complexity ahead of revenue synergies.
Q: What is Mankind Pharma share price target 2026?
Analyst consensus 12-month target is Rs 2,200–Rs 2,500 — implying 19–35% upside from Rs 1,850. Not guaranteed returns.
Q: Is Mankind Pharma a buy at current levels?
This article does not constitute investment advice. Consult a SEBI-registered financial advisor before investing.
Q: What are the key recovery catalysts for Mankind Pharma?
Primary recovery catalysts: Consumer health brands — Prega News 72% market share.
Q: What is Mankind Pharma’s market cap?
Mankind Pharma market cap is Rs 74,000 Cr at the current price of Rs 1,850.
Q: What is Mankind Pharma’s P/E ratio?
Mankind Pharma trailing P/E is 42x as of April 2026.
Q: What are the risks of investing in Mankind Pharma now?
Key risks: valuation at 42x P/E, sector headwinds, and macro uncertainty. Consult a SEBI-registered advisor.
Q: What is the long-term outlook for Mankind Pharma?
Short-term Rs 2,000–2,200; 12-month Rs 2,200–2,500; long-term Rs 3,000–3,500. Full details in the share price target section above.
Recent Articles
Why is KRBL Share Price Falling? Check Next Share Price Target
Why is Reliance Infrastructures Share Price Falling? Check Next Share Price Target
Why is Mahanagar Gas Share Price Falling? Check Next Share Price Target
Why is Happiest Minds Share Price Falling? Check Next Share Price Target
